Cited by 326Dementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration MechanismsAdipokines, Inflammation, and Metabolic Diseases

Systemic markers of inflammation and cognitive decline in old age

Open access
Schram, Miranda T., Euser, Sjoerd M., De Craen, Anton J. M., Witteman, Jacqueline C., Frölich, Marijke, Hofman, Albert, Jolles, Jelle, Breteler, Monique M. B. +1 more·2007·Journal of the American Geriatrics Society

Abstract

OBJECTIVES: To investigate whether higher circulating levels of C‐reactive protein (CRP), interleukin‐6 (IL‐6), and α1‐antichymotrypsin (ACT) are associated with worse cognitive function and decline in old age. DESIGN: Two independent population‐based cohort studies. SETTING: The Rotterdam Study (mean follow‐up 4.6 years) and the Leiden 85‐plus Study (maximal follow‐up 5 years). PARTICIPANTS: Three thousand eight hundred seventy‐four individuals, mean age 72, from the Rotterdam Study, and 491 individuals, all aged 85, from the Leiden 85‐plus Study. MEASUREMENTS: Both studies assessed global cognition, executive function, and memory. Linear regression analyses were used in the current study to investigate the associations between inflammatory markers and cognitive function and decline. RESULTS: In the Rotterdam Study, higher levels of CRP and IL‐6 were cross‐sectionally associated with worse global cognition and executive function ( P <.05). ACT was not associated with cognitive function. In the Leiden 85‐plus Study, estimates were similar for CRP, although not statistically significant. Higher IL‐6 levels were related to a steeper annual decline in memory function in the longitudinal analysis in the Leiden 85‐plus Study ( P <.05). The effect of higher IL‐6 levels on global and memory function decline was stronger in apolipoprotein E (APOE) ɛ4 carriers ( P ‐interaction=.01) than in those who were not ( P ‐interaction=.05). In the Rotterdam Study, higher IL‐6 levels were related to a steeper annual decline in global cognition in APOE ɛ4 carriers only. CONCLUSION: Systemic markers of inflammation are only moderately associated with cognitive function and decline and tend to be stronger in carriers of the APOE ɛ4 allele. Systemic markers of inflammation are not suitable for risk stratification.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1532-5415.2007.01159.x

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The increase of pro-inflammatory cytokines is associated with greater cognitive decline in old age.

    “the increase of the pro-inflammatory cytokines is associated with greater cognitive decline in old age”

    From ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease (2022) · cites this paper as Schram et al 2007

    The available copy shows the title and bibliographic metadata, but no findings about cytokine levels or cognitive decline. Searches for pro-inflammatory cytokines, interleukin-6, and cognitive decline returned no substantive passages, so the attributed association cannot be verified from this copy. (LLM, conf=0.73)

    Experimental — accuracy not yet measured
  • APOE ε4 carriers have higher levels of activated microglia and pro-inflammatory cytokines than non-ε4 carriers.

    “APOE ε4 carriers have higher levels of activated microglia and pro-inflammatory cytokines than non-ε4 carriers”

    From ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease (2022) · cites this paper as Schram et al 2007

    The available indexed passages contain bibliographic details rather than findings (the passage labeled Abstract has no substantive abstract text; no page is given). Searches for APOE ε4, activated microglia, and pro-inflammatory cytokines found no passage comparing carriers with non-carriers, so the claim cannot be assessed from our copy. (LLM, conf=0.70)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 32 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Schram, M. T., Euser, S. M., De Craen, A. J. M., Witteman, J. C., Frölich, M., Hofman, A., Jolles, J., Breteler, M. M. B., & Westendorp, R. G. J.
Affiliations
Leiden University Medical Center (NL)
Venue
Journal of the American Geriatrics Society
Publisher
Wiley
Published
2007-04-11
Volume
55
Issue
5
Pages
708-716
ISSN
  • 0002-8614 (ISSN-L)
  • 1532-5415
OpenAlex
W2073481032
Cited by
326
References
32
Citations by year
2026: 7 · 2025: 10 · 2024: 15 · 2023: 20 · 2022: 28 · 2021: 15 · 2020: 19 · 2019: 21 · 2018: 17 · 2017: 14 · 2016: 27 · 2015: 19 · 2014: 20 · 2013: 18 · 2012: 9
FWCI
10.65
Type
journal article
Language
en
Locations
  • Journal of the American Geriatrics Society (publishedVersion)
  • PubMed (publishedVersion)
  • Research Publications (Maastricht University) (publishedVersion, other-oa)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
  • Research Publications (Maastricht University) (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
Keywords
systemic inflammation, cognitive decline, C-reactive protein, interleukin-6, alpha-1-antichymotrypsin, APOE ε4, older adults, executive function, memory decline, global cognition, risk stratification
MeSH terms
Aged, Aged, 80 and over, alpha 1-Antichymotrypsin, C-Reactive Protein, Cognition Disorders, Female, Follow-Up Studies, Humans, Inflammation, Male, Middle Aged, Biomarkers, Interleukin-6, Inflammation Mediators, Apolipoprotein E4

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review